Du et al. found that CXCL12 and inflammatory fibroblasts act to regulate the tumour microenvironment in BLCA and can thus affect the outcome and efficacy of immunotherapy, further supporting the important role of CXCL12 in this disease [27]. This evidence concerns the gene CXCL12 and bladder transitional cell carcinoma.